Ticker: EWTX

Edgewise Therapeutics, Inc. (NASDAQ: EWTX) Update As of March 31, 2025, Edgewise Therapeutics continues to develop innovative treatments for severe muscle diseases, primarily through its lead candidates, sevasemten and EDG-7500. The company has engaged in multiple Phase 2 clinical trials and s...